BR112012007828A2 - compostos, processo para preparar os compostos, e, composição farmacêutica. - Google Patents

compostos, processo para preparar os compostos, e, composição farmacêutica.

Info

Publication number
BR112012007828A2
BR112012007828A2 BR112012007828A BR112012007828A BR112012007828A2 BR 112012007828 A2 BR112012007828 A2 BR 112012007828A2 BR 112012007828 A BR112012007828 A BR 112012007828A BR 112012007828 A BR112012007828 A BR 112012007828A BR 112012007828 A2 BR112012007828 A2 BR 112012007828A2
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical composition
preparing
relates
xanthine oxidase
Prior art date
Application number
BR112012007828A
Other languages
English (en)
Other versions
BR112012007828B8 (pt
BR112012007828B1 (pt
Inventor
Cheol Kyu Jung
Deok Seong Park
Eun Sil Choi
Geun Tae Kim
Heui Sul Park
Hyun Jung Park
Jeong Uk Song
Ki Chul Koo
Sun Pil Choi
Tae Hun Kim
Vasily Artemov
Wan Su Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012007828(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BR112012007828A2 publication Critical patent/BR112012007828A2/pt
Publication of BR112012007828B1 publication Critical patent/BR112012007828B1/pt
Publication of BR112012007828B8 publication Critical patent/BR112012007828B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos, processo para preparar os compostos, e, composição farmacêutica - a presente invenção diz respeito a novos compostos que sãoeficazes como um inibidor para xantina oxidase, um processo para preparar a mesma e uma composição farmacêutica que compreende uma quantidade terapeuticamente eficaz dos mesmos.
BR112012007828A 2009-10-07 2010-10-04 compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase BR112012007828B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0095363 2009-10-07
KR20090095363 2009-10-07
PCT/KR2010/006760 WO2011043568A2 (en) 2009-10-07 2010-10-04 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Publications (3)

Publication Number Publication Date
BR112012007828A2 true BR112012007828A2 (pt) 2016-03-08
BR112012007828B1 BR112012007828B1 (pt) 2021-01-12
BR112012007828B8 BR112012007828B8 (pt) 2021-05-25

Family

ID=43857261

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007828A BR112012007828B8 (pt) 2009-10-07 2010-10-04 compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase

Country Status (27)

Country Link
US (1) US8729273B2 (pt)
EP (1) EP2467378B1 (pt)
JP (1) JP5702392B2 (pt)
KR (1) KR101751325B1 (pt)
CN (1) CN102574839B (pt)
AP (1) AP3346A (pt)
AR (1) AR078504A1 (pt)
AU (1) AU2010304091B2 (pt)
BR (1) BR112012007828B8 (pt)
CA (1) CA2774133C (pt)
CL (1) CL2012000738A1 (pt)
CO (1) CO6430501A2 (pt)
EA (1) EA021025B1 (pt)
EC (1) ECSP12011793A (pt)
ES (1) ES2599829T3 (pt)
HK (1) HK1170224A1 (pt)
IL (1) IL218669A (pt)
MA (1) MA33880B1 (pt)
MX (1) MX2012003782A (pt)
MY (1) MY162813A (pt)
PE (1) PE20121088A1 (pt)
SG (1) SG179186A1 (pt)
TR (1) TR201203989T1 (pt)
TW (1) TWI423962B (pt)
UA (1) UA110197C2 (pt)
WO (1) WO2011043568A2 (pt)
ZA (1) ZA201202544B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CA2844128C (en) * 2011-08-30 2020-09-01 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ME03055B (me) 2013-03-29 2018-10-20 Teijin Pharma Ltd Derivat pirazola
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
CN104774172B (zh) * 2015-04-08 2017-03-22 河南师范大学 一种3‑氰基吲哚类化合物的合成方法
AU2016316278B2 (en) * 2015-09-02 2020-06-04 Sunshine Lake Pharma Co., Ltd. Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
WO2018157801A1 (zh) * 2017-02-28 2018-09-07 广东东阳光药业有限公司 氰基取代的稠合双环衍生物及其制备方法和用途
CA3100308C (en) * 2018-06-01 2024-02-20 Autophagysciences Inc. Compound and pharmaceutical composition comprising the same
CN111072647B (zh) * 2019-12-11 2021-02-26 沈阳药科大学 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
US20240000750A1 (en) 2020-11-04 2024-01-04 Lg Chem, Ltd. Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same
KR20220077091A (ko) 2020-12-01 2022-06-08 주식회사 엘지화학 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제
JP2023551524A (ja) 2020-12-01 2023-12-08 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤、およびその製造方法
CN112920170B (zh) * 2021-01-29 2023-06-20 中国医科大学 N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途
JP2024511899A (ja) 2021-04-16 2024-03-15 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む経口用製剤
WO2022231262A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제의 제조 방법
WO2022231263A1 (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
KR20220147529A (ko) * 2021-04-27 2022-11-03 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
WO2022233264A1 (zh) 2021-04-29 2022-11-10 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂
AU2022294728A1 (en) 2021-06-15 2024-01-04 Lg Chem, Ltd. Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
AR126164A1 (es) 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
TWI822151B (zh) 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
WO2023277658A1 (ko) 2021-07-02 2023-01-05 주식회사 엘지화학 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법
CN116715633A (zh) * 2022-04-27 2023-09-08 江苏新元素医药科技有限公司 可用于降尿酸的化合物
WO2023208103A1 (zh) * 2022-04-27 2023-11-02 江苏新元素医药科技有限公司 可用于痛风的化合物
CN116283946B (zh) * 2023-03-27 2024-05-07 武汉工程大学 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU218942B (hu) 1990-11-30 2001-01-29 Teijin Ltd. 2-Fenil-tiazol-származékok, az ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US6635640B2 (en) * 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
ES2250422T3 (es) * 2000-07-10 2006-04-16 Bristol-Myers Squibb Company Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos.
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
EP1911760A4 (en) * 2005-07-01 2010-06-02 Nippon Chemiphar Co xanthine oxidase inhibitor
BRPI0616939A2 (pt) * 2005-10-07 2011-07-05 Astellas Pharma Inc derivado de ácido triarilacarboxìlico
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2008179621A (ja) * 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
WO2008126770A1 (ja) 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
CN101679251B (zh) * 2007-04-11 2013-10-02 橘生药品工业株式会社 (氮杂)吲哚衍生物及其医药用途
US8227500B2 (en) 2007-04-11 2012-07-24 Kissei Pharmaceutical Co., Ltd. 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
EP2338887A4 (en) * 2008-10-15 2012-05-09 Kissei Pharmaceutical FUSIONED HETEROCYCLIC DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
JP5688660B2 (ja) 2008-10-16 2015-03-25 オートマチック バー コントロールス インコーポレイテッド 食物製品のオンデマンド分配のための機器および方法およびターンテーブル
US8785489B2 (en) * 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
WO2011036130A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators

Also Published As

Publication number Publication date
CL2012000738A1 (es) 2012-09-14
CN102574839B (zh) 2015-11-25
AU2010304091B2 (en) 2016-06-09
MX2012003782A (es) 2012-08-31
UA110197C2 (ru) 2015-12-10
IL218669A (en) 2016-08-31
IL218669A0 (en) 2012-05-31
EP2467378B1 (en) 2016-07-27
EP2467378A2 (en) 2012-06-27
CN102574839A (zh) 2012-07-11
JP2013507355A (ja) 2013-03-04
MA33880B1 (fr) 2013-01-02
JP5702392B2 (ja) 2015-04-15
CO6430501A2 (es) 2012-04-30
WO2011043568A3 (en) 2011-09-29
EA021025B1 (ru) 2015-03-31
ES2599829T3 (es) 2017-02-03
KR20110037883A (ko) 2011-04-13
US20120184582A1 (en) 2012-07-19
BR112012007828B8 (pt) 2021-05-25
TR201203989T1 (tr) 2012-09-21
AP2012006191A0 (en) 2012-04-30
AU2010304091A1 (en) 2012-04-19
HK1170224A1 (zh) 2013-02-22
CA2774133A1 (en) 2011-04-14
ECSP12011793A (es) 2012-05-30
EP2467378A4 (en) 2013-04-24
MY162813A (en) 2017-07-31
BR112012007828B1 (pt) 2021-01-12
SG179186A1 (en) 2012-05-30
TWI423962B (zh) 2014-01-21
EA201270520A1 (ru) 2012-10-30
CA2774133C (en) 2019-06-25
TW201118077A (en) 2011-06-01
ZA201202544B (en) 2012-12-29
WO2011043568A2 (en) 2011-04-14
AP3346A (en) 2015-07-31
KR101751325B1 (ko) 2017-06-27
US8729273B2 (en) 2014-05-20
PE20121088A1 (es) 2012-08-17
AR078504A1 (es) 2011-11-09

Similar Documents

Publication Publication Date Title
BR112012007828A2 (pt) compostos, processo para preparar os compostos, e, composição farmacêutica.
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BR112014030473A2 (pt) novo diazaespirocicloalcano e azaespirocicloalcano
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
BR112014029139A8 (pt) compostos inibidores da atividade de catecol o-metiltransferase
BR112013011441B8 (pt) Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112014028042A2 (pt) inibidores de nampt
ECSP14004595A (es) 2-tiopirimidinonas
BRPI1014802B8 (pt) profármacos de triptolida.
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112012009310B8 (pt) composto derivados de 2-oxo-1-pirrolidinil imidazotiadiazol, uso dos mesmos e composição farmacêutica compreendendo os mesmos
BR112018072755A2 (pt) composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica
BR112012021476A2 (pt) composto, processo para preparação do composto, composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz do composto e emprego de tal composto
CO6321288A2 (es) Sales de compuestos inhibidores de vih
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25G Requested change of headquarter approved

Owner name: LG LIFE SCIENCES LTD (KR)

B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD (KR)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF